| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ECE3; CD238 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human KEL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于CRTH2抗体的代表性文献摘要(模拟示例，非真实文献)：
---
1. **文献名称**：*CRTH2 Antagonism in Asthma: Mechanisms and Therapeutic Potential*
**作者**：Hirai, H., Nagata, K.
**摘要**：探讨CRTH2作为前列腺素D2受体的结构和功能，分析其介导Th2细胞趋化及炎症反应的机制，提出靶向CRTH2的单克隆抗体在哮喘治疗中的潜力。
2. **文献名称**：*A Phase II Trial of Anti-CRTH2 Antibody in Eosinophilic Asthma*
**作者**：Singh, D., et al.
**摘要**：一项II期临床试验，评估CRTH2抗体(如OC000459)对哮喘患者气道炎症和症状的影响，显示其显著降低嗜酸性粒细胞水平并改善肺功能。
3. **文献名称**：*CRTH2 in Allergic Diseases: From Biomarker to Therapeutic Target*
**作者**：Pettipher, R., Hansel, T.T.
**摘要**：综述CRTH2在过敏性鼻炎、特应性皮炎等疾病中的作用，强调其抗体在阻断炎症通路中的应用前景及临床研究进展。
4. **文献名称**：*CRTH2-Specific Antibodies for Diagnostic Imaging of Th2 Inflammation*
**作者**：Marion, S., et al.
**摘要**：开发靶向CRTH2的放射性标记抗体，用于体内炎症灶的分子成像，证实其在定位Th2型炎症中的高特异性，可能推动精准诊断工具的发展。
---
注：以上文献为模拟示例，实际研究需通过PubMed/Google Scholar等平台检索真实文献。
CRTH2 (Chemoattractant Receptor-Homologous Molecule expressed on Th2 cells), also known as prostaglandin D2 receptor 2 (PTGDR2), is a G protein-coupled receptor primarily expressed on Th2 lymphocytes, eosinophils, basophils, and other immune cells involved in type 2 inflammation. It binds prostaglandin D2 (PGD2), a lipid mediator critical in allergic responses, triggering chemotaxis, cell activation, and cytokine release. CRTH2 antibodies are therapeutic or research tools designed to block this receptor, thereby inhibiting PGD2-driven inflammatory pathways.
Developed to target allergic diseases like asthma, atopic dermatitis, and allergic rhinitis, CRTH2 antagonists (including monoclonal antibodies and small molecules) aim to disrupt the recruitment and activation of pro-inflammatory cells. Preclinical studies show that CRTH2 inhibition reduces eosinophil infiltration, Th2 cytokine production, and airway hyperresponsiveness. Clinical trials have demonstrated mixed efficacy, with some agents improving symptoms in asthma or eczema, while others showed limited benefits, highlighting heterogeneity in patient responses.
Research also explores CRTH2's role in eosinophilic disorders and COVID-19-related inflammation. Challenges include optimizing receptor specificity and understanding downstream signaling effects. Despite setbacks, CRTH2 remains a compelling target for immune modulation, with ongoing studies refining therapeutic strategies to enhance precision in allergic and eosinophilic disease management.
×
